# BioNexus Gene Lab Corp. (BGLC)

> Source: Nexqual · https://nexqual.com/BGLC · data as of 2026-10-23 20:00 UTC · cite as "Nexqual, BioNexus Gene Lab Corp. (BGLC), nexqual.com/BGLC" · informational, not investment advice.

**Price:** USD 1.19 (+0.00% on the day) · last close of Oct 23, 2026; US market closed, not a live price. Prev close 1.19 · day 1.19–1.19 · 52w 1.07–5.67 · market cap $3.5M · NCM

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $3.1M, net income -$2.6M (-82.4% margin), free cash flow -$854K (SEC filings).
- Analysts: None.
- Total return with dividends: 1Y -76.6% vs S&P 500 +13.4%; 5Y -99.5% vs S&P 500 +76.9%.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $13.4M | $10.9M | $9.8M | $9.5M | $7.4M | $3.1M |
| Gross profit | $2.3M | $1.3M | $1.3M | $1.3M | $1.1M | — |
| Operating income | $1.1M | -$291K | -$2.6M | -$1.6M | -$3.0M | -$2.6M |
| Net income | $752K | -$356K | -$2.6M | -$1.6M | -$3.0M | -$2.6M |
| EPS (diluted) | — | — | -$0.17 | -$0.09 | — | — |
| Free cash flow | $6K | $552K | -$2.0M | -$2.3M | -$1.9M | -$854K |
| Gross margin | 17.0% | 11.5% | 13.6% | 13.6% | 14.6% | — |
| Operating margin | 7.9% | -2.7% | -26.5% | -16.5% | -39.9% | -81.8% |
| Net margin | 5.6% | -3.3% | -26.9% | -16.8% | -40.2% | -82.4% |
| Revenue growth | +17.3% | -18.2% | -10.6% | -2.7% | -21.9% | — |
| Cash + short-term investments | $2.1M | $2.1M | $4.5M | $2.9M | $2.4M | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/S 1.1x · P/B 0.5x · FCF yield -24.45% · Earnings yield -73.77%

## Analysts
Consensus None.

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-24) | 5Y (from 2021-10-25) |
|---|---|---|
| Total return | -76.6% | -99.5% |
| S&P 500 (SPY) | +13.4% | +76.9% |
| Per year | -76.7% | -65.0% |
| Volatility (annualized) | 68.7% | 161.6% |
| Max drawdown | -78.3% (Nov 2025→Oct 2026) | -99.5% (Dec 2021→Oct 2026) |

## Peers (Specialty Chemicals)
BCPC (Balchem Corporation) USD 177 +2.18% · SXT (Sensient Technologies Corporati) USD 132.65 +1.31% · AXTA (Axalta Coating Systems Ltd.) USD 34.14 -2.60% · EMN (Eastman Chemical Company) USD 64.93 -0.58% · NEU (NewMarket Corp) USD 870.6 -0.65% · ESI (Element Solutions Inc.) USD 33.21 +0.30%

## More
Full page: https://nexqual.com/BGLC · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Revenue by region (quarter ended 2026-06-30)

| Line | Revenue | Share | YoY |
|---|---|---|---|
| Myanmar (Burma) | $63,717 | 83.7% | -96.5% |
| South Africa | $12,439 | 16.3% | — |
| Total revenue | $76,156 | 100% | — |

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter | — | — | — | $0 | — |
| Next quarter | — | — | — | $0 | — |
| Current fiscal year | — | — | — | $0 | — |
| Next fiscal year | — | — | — | $0 | — |